Ezra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Ezra Cohen, MD, FRCPSC, FASCO, professor of medicine, associate director, translational science, Moores Cancer Center, University of California San Diego, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Cohen says first, patients need to be educated on the toxicities that could present themselves and should notify their physician immediately should any symptoms appear. Cohen also says that the earlier the symptoms are seen, the easier it is to manage these toxicities and avoid them from escalating to life-threatening situations.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More